Authors: Phil Dalgarno, Steve O’Rawe, Richard Hammersley Published: April 28, 2021 This paper investigates options available to policy makers responding to the challenges of drug use in modern society, focussing on the UK. It investigates the failings of prohibition policy that has driven historic reactions to drugs, drug use and drug users globally, nationally and  …

Authors: David V Gauvin, Zachary J Zimmermann, Mary Jeanne Kallman Published: March 17, 2021 The trends in addiction medicine suggest that much of the historical gender differences in the prevalence of both substance use and substance use disorders may be attributable to social and cultural factors and not biological sex differences. The current total weight  …

Authors: Kenzi Riboulet-Zemouli Published: December 29, 2020 Objective Identify a coherent nomenclature for Cannabis sativa L. derived products and their analogues.   Design Research undertaken in parallel to the three-year assessment of Cannabis derivatives by the World Health Organisation. The scope is limited to Cannabis products intended for human incorporation (internal and topical consumption). Primarily  …

Authors: RR Zafar, AK Schlag, DJ Nutt Published: December 9, 2020 An audit of the impact of medical cannabis in 10 patients with severe epilepsy. Background Scientific and anecdotal evidence suggest that whole-plant cannabis extracts are effective in reducing seizure frequency in individuals with a range of epileptic etiologies. We report a case series of  …

Authors: Jacob S Aday, Emily K Bloesch, Christopher C Davoli Published: November 25, 2020 Public and scientific interest into psychedelic drugs has grown steadily over much of the last two decades, before an exponential increase in recent years. We contend that 2019, in particular, involved myriad notable changes in the science, industry, and deregulation of  …

Authors: JEC Anthony, A Winstock, JA Ferris, DJ Nutt Published: November 2, 2020 It is well documented that psychedelic drugs can have a profound effect on colour perception. After previous research involving psychedelic drug ingestion, several participants had written to the authors describing how symptoms of their colour blindness had improved. The Global Drugs Survey  …

Authors: James A Foulds, David Nutt Published: July 27, 2020 Methamphetamine was reclassified as a Class A drug in New Zealand in 2003. This meant harsher sentences for people convicted of its manufacture, importation or supply. Despite this, the number of convictions for methamphetamine-related offending continued to increase. In 2019, the New Zealand Court of  …